Statistiche di base
| LEI | 5493008K7TB0IKP37H79 |
| CIK | 886163 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ligand Pharmaceuticals Incorporated
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| May 18, 2026 |
AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER EX-2.1 Exhibit 2.1 AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this “Amendment”) is made as of May 16, 2026, with respect to that certain Agreement and Plan of Merger, dated as of April 27, 2026 (the “Merger Agreement”), by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Parent”), Flex Merger Sub, Inc., a Nevada |
|
| May 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2026 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of incorporation or |
|
| May 18, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2026 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of incorpora |
|
| May 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2026 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMACEUT |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File N |
|
| May 7, 2026 |
Ligand Reports First Quarter 2026 Financial Results First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a. |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2026 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission Fil |
|
| April 28, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 28, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 27, 2026 |
DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 27, 2026 |
EX-99.2 Ligand Acquisition of XOMA Royalty Corporation APRIL 27, 2026 Exhibit 99.2 Safe Harbor Statement & Disclaimers Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including information about, among other topics, Ligand’s proposed acquis |
|
| April 27, 2026 |
EX-10.1 Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT, dated as of April 27, 2026 (this “Agreement”), is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Parent”), and each of the signatories named on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). RECITALS WHEREAS, each Stockholder is, a |
|
| April 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of incorporation o |
|
| April 27, 2026 |
EX-99.1 Exhibit 99.1 Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across development stages, |
|
| April 27, 2026 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among LIGAND PHARMACEUTICALS INCORPORATED as Parent FLEX MERGER SUB, INC. as Merger Sub and XOMA ROYALTY CORPORATION as the Company Dated as of April 27, 2026 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.1 The Mergers 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Effects of the Merger 2 Section 1.5 Articles of Inc |
|
| April 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-33093 LIGAND PHARMACEUTICALS INCO |
|
| April 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| February 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-33093 LIGAND PHARMACEUTICALS INCO |
|
| February 27, 2026 |
EX-1.2 Exhibit 1.2 LIGAND PHARMACEUTICALS INCORPORATED Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT February 27, 2026 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Ligand Pharmaceuticals Incorporated, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “A |
|
| February 27, 2026 |
Exhibit 21.1 LIGAND PHARMACEUTICALS INCORPORATED LIST OF SUBSIDIARIES* Name Jurisdiction of Incorporation Apeiron Biologics GmbH Austria CyDex Pharmaceuticals, Inc. Delaware Ligand Holdings UK Ltd. England and Wales Ligand UK Development Limited England and Wales Ligand UK Limited England and Wales Metabasis Therapeutics, Inc. Delaware Neurogen Corporation Delaware Pfenex Inc. Delaware Pharmacopei |
|
| February 27, 2026 |
LIGAND PHARMACEUTICALS INCORPORATED Dated as of , 20 EX-4.3 Exhibit 4.3 LIGAND PHARMACEUTICALS INCORPORATED INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. |
|
| February 27, 2026 |
Calculation of Filing Fee Tables S-3 LIGAND PHARMACEUTICALS INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0. |
|
| February 27, 2026 |
As filed with the Securities and Exchange Commission on February 27, 2026 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 27, 2026 Registration No. |
|
| February 26, 2026 |
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share1 of $8. |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission |
|
| December 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2025 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of incorporatio |
|
| November 7, 2025 |
LIGAND PHARMACEUTICALS INCORPORATED INSIDER TRADING COMPLIANCE PROGRAM Exhibit 19.1 LIGAND PHARMACEUTICALS INCORPORATED INSIDER TRADING COMPLIANCE PROGRAM CP-LAW-001 This Insider Trading Compliance Program (the “Program”) consists of five sections: Section I provides an overview; Section II sets forth the policies of Ligand Pharmaceuticals Incorporated (the “Company”) prohibiting insider trading; Section III explains insider trading; Section IV consists of various pr |
|
| November 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMA |
|
| November 6, 2025 |
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings per diluted share1 increased to $7. |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission F |
|
| October 1, 2025 |
144 0001223000 XXXXXXXX LIVE 0000886163 LIGAND PHARMACEUTICALS INC 001-33093 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500 KOZARICH JOHN W Director Common UBS Financial Services, Inc. |
|
| September 23, 2025 |
144 0001376960 XXXXXXXX LIVE 0000886163 LIGAND PHARMACEUTICALS INCORPORATED 001-33093 555 Heritage Drive, Suite 200 Jupiter FL 33458 (858) 550-7500 JASON M ARYEH Director Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 10000 1708087. |
|
| September 17, 2025 |
144 0001376960 XXXXXXXX LIVE 0000886163 LIGAND PHARMACEUTICALS INC 001-33093 555 Heritage Drive, Suite 200 Jupiter FL 33458 858-550-7500 Aryeh Jason Director Common Stock Charles Schwab & Co 3000 Schwab Way Westlake TX 76262 10000 1685000. |
|
| September 16, 2025 |
THIRD AMENDMENT TO CREDIT AGREEMENT EX-10.1 Exhibit 10.1 WARNING: The following actions may trigger Austrian stamp duty: (a) this document is signed in Austria; (b) the original, or a certified copy, of this document or of a Substitute Document (as defined below) (all such documents being “Stamp Duty Sensitive Documents”) is brought into Austria (including by way of fax and email); and/or (c) a Substitute Document is created in Aust |
|
| September 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2025 (September 12, 2025) LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisd |
|
| September 2, 2025 |
144 0001223000 XXXXXXXX LIVE 0000886163 LIGAND PHARMACEUTICALS INC 001-33093 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500 KOZARICH JOHN W Director Common UBS Financial Services, Inc. |
|
| August 14, 2025 |
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering EX-99.1 Exhibit 99.1 Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering JUPITER, Fla., August 11, 2025 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably |
|
| August 14, 2025 |
EX-10.2 Exhibit 10.2 THE SECURITIES REPRESENTED HEREBY (THE “WARRANTS”) WERE ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND THE WARRANTS MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR AN APPLICABLE EXEMPTION FROM THE REGISTRA |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of incorporation |
|
| August 14, 2025 |
EX-10.1 Exhibit 10.1 [Dealer Name] [Dealer Address] August [ ], 2025 To: Ligand Pharmaceuticals Incorporated 555 Heritage Drive, Suite 200 Jupiter FL, 33458 Re: [Base]1[Additional]2 Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer] (“Dealer”) and Ligand Pharmaceutica |
|
| August 14, 2025 |
EX-4.1 Exhibit 4.1 Execution Version LIGAND PHARMACEUTICALS INCORPORATED AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of August 14, 2025 0.75% Convertible Senior Notes due 2030 TABLE OF CONTENTS Page ARTICLE 1 Definitions Section 1.01. Definitions. 5 Section 1.02. References to Interest. 18 ARTICLE 2 Issue, Description, Execution, Registration and Exchange of No |
|
| August 14, 2025 |
Ligand Announces Closing of Convertible Senior Notes Offering EX-99.2 Exhibit 99.2 Ligand Announces Closing of Convertible Senior Notes Offering JUPITER, Fla., August 14, 2025 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.75% convertible senior notes due 2030 (the “notes”). The aggregate principal amount of the notes sold in the offeri |
|
| August 11, 2025 |
SECOND AMENDMENT TO CREDIT AGREEMENT EX-10.1 Exhibit 10.1 EXECUTION VERSION WARNING: The following actions may trigger Austrian stamp duty: (a) this document is signed in Austria; (b) the original, or a certified copy, of this document or of a Substitute Document (as defined below) (all such documents being “Stamp Duty Sensitive Documents”) is brought into Austria (including by way of fax and email); and/or (c) a Substitute Document |
|
| August 11, 2025 |
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 EX-99.1 Exhibit 99.1 Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 JUPITER, Fla., August 11, 2025 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to pers |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of incorporation |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMACEUTI |
|
| August 7, 2025 |
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings per diluted share1 increased to $6. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission Fil |
|
| July 2, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2025 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| July 2, 2025 |
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI Pelthos will commence trading on the NYSE American exchange under the new ticker symbol “PTHS” on July 2, 2025 JUPITER, Fla. |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMACEUT |
|
| May 9, 2025 |
Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT LIGAND PHARMACEUTICALS INCORPORATED TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version PURCHASE AND SALE AGREEMENT dated as of February 24, 2025 by and among CASTLE CREEK BIOSCIENCES, INC. and CASTLE CREEK BIOSCIENCES, LLC, as Se |
|
| May 8, 2025 |
Ligand Reports First Quarter 2025 Financial Results First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File N |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 22, 2025 |
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K È ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACT OF1934 FortheFiscalYearEndedDecember31,2024 ‘ TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGE ACTOF1934 OR Forthetransitionperiodfrom to . CommissionFileNo.001-33093 LIGANDPHARMACEUTICALSINCORPORATED (Exactnameofregistrantasspecifiedinitsch |
|
| April 17, 2025 |
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos’ ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI Transaction is expected to close in the summer of 2025 JUPITER, Fla. |
|
| April 17, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission Fil |
|
| February 28, 2025 |
LIGAND PHARMACEUTICALS INCORPORATED INSIDER TRADING COMPLIANCE PROGRAM Exhibit 19.1 LIGAND PHARMACEUTICALS INCORPORATED INSIDER TRADING COMPLIANCE PROGRAM CP-LAW-001 This Insider Trading Compliance Program (the “Program”) consists of five sections: Section I provides an overview; Section II sets forth the policies of Ligand Pharmaceuticals Incorporated (the “Company”) prohibiting insider trading; Section III explains insider trading; Section IV consists of various pr |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-33093 LIGAND PHARMACEUTICALS INCO |
|
| February 28, 2025 |
Exhibit 21.1 LIGAND PHARMACEUTICALS INCORPORATED LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Apeiron Biologics GmbH Austria CyDex Pharmaceuticals, Inc. Delaware LHNC, Inc. Delaware Ligand Holdings UK Ltd. England and Wales Ligand UK Development Limited England and Wales Ligand UK Limited England and Wales Metabasis Therapeutics, Inc. Delaware Neurogen Corporation Delaware Pelthos Thera |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission |
|
| February 27, 2025 |
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission |
|
| February 25, 2025 |
FOR IMMEDIATE RELEASE Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla. |
|
| February 5, 2025 |
EX-24 2 PowerOfAttorney.txt EXHIBIT 24: POWER OF ATTORNEY POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, Jam |
|
| February 5, 2025 |
EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 BlackRock Advisors, LLC Aperio Group, LLC BlackRock (Netherlands) B.V. BlackRock Fund Advisors* BlackRock Institutional Trust Company, National Association BlackRock Asset Management Ireland Limited BlackRock Financial Management, Inc. BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC BlackRock Investment Management (UK) Limited BlackRo |
|
| November 14, 2024 |
SC 13G/A 1 Ligand093024.txt JANUS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 5* Name of Issuer: LIGAND PHARMACEUTICALS INCORPORATED Title of Class of Securities: Common Stock CUSIP Number: 53220K504 Date of Event Which Requires Filing of this Statement: 9/30/2024 Check the appropriate box t |
|
| November 8, 2024 |
LGND / Ligand Pharmaceuticals Incorporated / GOLDMAN SACHS GROUP INC Passive Investment SC 13G/A 1 LIGANDPHARM.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* LIGAND PHARMACEUTICALS INCORPORATED - (Name of Issuer) Common Stock, par value $0.001 per share - (Title of Class of Securities) 53220K504 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this State |
|
| November 8, 2024 |
SEVERANCE AGREEMENT AND GENERAL RELEASE Exhibit 10.2 SEVERANCE AGREEMENT AND GENERAL RELEASE THIS SEVERANCE AGREEMENT AND GENERAL RELEASE (hereinafter this “AGREEMENT”) is made effective as of the 2nd day of August, 2024 by and between Matthew Korenberg (hereinafter “Korenberg”) and LIGAND PHARMACEUTICALS INCORPORATED (hereinafter “LIGAND”) and inures to the benefit of each of LIGAND’s parents, subsidiaries, related entities, predecesso |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMA |
|
| November 7, 2024 |
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously$140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5. |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission F |
|
| November 1, 2024 |
EX-99.A 2 d885877dex99a.htm EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this [7th] day of FEBRUARY, 2024 by and between Delaware Funds by Macquarie,® Optimum Fund Trust and Macquarie ETF Trust listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectiv |
|
| November 1, 2024 |
LGND / Ligand Pharmaceuticals Incorporated / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A 1 d885877dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ligand Pharmaceuticals Inc (Name of Issuer) Common Shares (Title of Class of Securities) 53220K504 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 1, 2024 |
EX-99.B 3 d885877dex99b.htm EX-99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited incorporated by reference to 13G filings made by Macquarie Group Limited on June 7, 2023. Page 13 of 13 |
|
| August 7, 2024 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT LIGAND PHARMACEUTICALS INCORPORATED TREATS AS PRIVATE OR CONFIDENTIAL. PURCHASE AND SALE AGREEMENT dated as of May 6, 2024 by and among AGENUS INC., AGENUS ROYALTY FUND, LLC, AGENUS HOLDINGS 2024, LLC and LIGAND PHARMACEUTICALS IN |
|
| August 7, 2024 |
FIRST AMENDMENT TO CREDIT AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), is made and entered into as of July 8, 2024, by and among LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation (the “Borrower”), the other Loan Parties party hereto, the Lenders party hereto (the “Lenders”), and CITIBANK, N.A., as administrative agent for the Lenders (in such capaci |
|
| August 7, 2024 |
Agreement on the Acquisition of Stocks Apeiron Biologics AG SPA Execution Version CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT LIGAND PHARMACEUTICALS INCORPORATED TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMACEUTI |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission Fil |
|
| August 6, 2024 |
Ligand Reports Second Quarter 2024 Financial Results Conference call at 4:30 p.m. Eastern Time today Ligand Reports Second Quarter 2024 Financial Results Conference call at 4:30 p.m. Eastern Time today JUPITER, Fla., August 06, 2024 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission Fil |
|
| July 17, 2024 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| July 9, 2024 |
As filed with the Securities and Exchange Commission on July 9, 2024 As filed with the Securities and Exchange Commission on July 9, 2024 Registration No. |
|
| July 9, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Ligand Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| July 8, 2024 |
FOR IMMEDIATE RELEASE Ligand to Acquire APEIRON Biologics AG for $100 Million Acquisition provides Ligand with the royalty rights to QARZIBA®, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S. |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMACEUT |
|
| May 7, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File N |
|
| May 7, 2024 |
Ligand Reports First Quarter 2024 Financial Results Conference Call Begins at 4:30 p. |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File N |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from to . Commission File No. 001-33093 LIGAND PHARMACEUTICALS INCO |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 19, 2024 |
FIFTH AMENDED AND RESTATED BYLAWS LIGAND PHARMACEUTICALS INCORPORATED ARTICLE I Exhibit 3.1 FIFTH AMENDED AND RESTATED BYLAWS OF LIGAND PHARMACEUTICALS INCORPORATED ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be in the City of Dover, County of Kent, State of Delaware. Section 2. Other Offices. The corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission Fil |
|
| March 1, 2024 |
As filed with the Securities and Exchange Commission on March 1, 2024 As filed with the Securities and Exchange Commission on March 1, 2024 Registration No. |
|
| March 1, 2024 |
Calculation of Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Ligand Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| March 1, 2024 |
Amendment to the 2022 Employment Inducement Plan Exhibit 10.2 AMENDMENT TO THE LIGAND PHARMACEUTICALS INCORPORATED 2022 EMPLOYMENT INDUCEMENT PLAN THIS AMENDMENT TO THE LIGAND PHARMACEUTICALS INCORPORATED 2022 EMPLOYMENT INDUCEMENT PLAN (this “Amendment”), effective as of January 30, 2024, is made and adopted by Ligand Pharmaceuticals Incorporated, a Delaware corporation (the “Company”). Capitalized terms used but not otherwise defined herein sh |
|
| February 29, 2024 |
LIGAND PHARMACEUTICALS INCORPORATED POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97 LIGAND PHARMACEUTICALS INCORPORATED POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Ligand Pharmaceuticals Incorporated (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). |
|
| February 29, 2024 |
AMENDMENT TO LIGAND PHARMACEUTICALS INCORPORATED 2022 EMPLOYMENT INDUCEMENT PLAN Exhibit 10.12 AMENDMENT TO LIGAND PHARMACEUTICALS INCORPORATED 2022 EMPLOYMENT INDUCEMENT PLAN THIS AMENDMENT TO THE LIGAND PHARMACEUTICALS INCORPORATED 2022 EMPLOYMENT INDUCEMENT PLAN (this “Amendment”), effective as of January 30, 2024, is made and adopted by Ligand Pharmaceuticals Incorporated, a Delaware corporation (the “Company”). Capitalized terms used but not otherwise defined herein shall |
|
| February 29, 2024 |
Exhibit 21.1 LIGAND PHARMACEUTICALS INCORPORATED LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Allergan Ligand Retinoid Therapeutics, Inc. Delaware Aramed Inc. Delaware Cita NeuroPharmaceuticals Inc. Canada CyDex Pharmaceuticals, Inc. Delaware LHNC, Inc. Delaware Ligand Holdings UK Limited England and Wales Ligand JVR, Inc. Delaware Ligand Pharmaceuticals International, Inc. Delaware Lig |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-33093 LIGAND PHARMACEUTICALS INCO |
|
| February 29, 2024 |
FIRST AMENDMENT TO DEVELOPMENT FUNDING AND ROYALTIES AGREEMENT Exhibit 10.44 FIRST AMENDMENT TO DEVELOPMENT FUNDING AND ROYALTIES AGREEMENT This First Amendment to Development Funding and Royalties Agreement (this “Amendment”) is made effective as of May 22, 2020 (the “Amendment Effective Date”) by and between Ligand Pharmaceuticals Incorporated, a Delaware corporation (the “Ligand”), and Palvella Therapeutics, Inc., a Delaware corporation (“Palvella” and, to |
|
| February 29, 2024 |
Exhibit 10.45 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE LIGAND PHARMACEUTICALS INCORPORATED HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO LIGAND PHARMACEUTICALS INCORPORATED IF PUBLICLY DISCLOSED. Execution Version AMENDMENT NO. 2 TO DEVELOPMENT FUNDING AND ROYALTIES AGREEMENT THIS AME |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission |
|
| February 27, 2024 |
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast at 8:30 a. |
|
| February 14, 2024 |
EX-99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited incorporated by reference to 13G filings made by Macquarie Group Limited on June 7, 2023. Page 13 of 13 |
|
| February 14, 2024 |
EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this [7th] day of FEBRUARY, 2024 by and between Delaware Funds by Macquarie,® Optimum Fund Trust and Macquarie ETF Trust listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “part |
|
| February 14, 2024 |
LGND / Ligand Pharmaceuticals Incorporated / MACQUARIE GROUP LTD - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Ligand Pharmaceuticals Inc (Name of Issuer) Common Shares (Title of Class of Securities) 53220K504 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 13, 2024 |
SC 13G/A 1 ligand123123.txt JHG PLC OWNS >5% UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 4* Name of Issuer: LIGAND PHARMACEUTICALS INCORPORATED Title of Class of Securities: Common Stock CUSIP Number: 53220K504 Date of Event Which Requires Filing of this Statement: 12/31/2023 Check the appropriate box |
|
| February 13, 2024 |
LGND / Ligand Pharmaceuticals Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Ligand Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 53220K504 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 12, 2024 |
LGND / Ligand Pharmaceuticals Incorporated / GOLDMAN SACHS GROUP INC Passive Investment SC 13G 1 LIGAND.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LIGAND PHARMACEUTICALS INCORPORATED - (Name of Issuer) Common Stock, par value $0.001 per share - (Title of Class of Securities) 53220K504 - (CUSIP Number) December 29, 2023 - (Date of Event Which Requires Filing of this Statement) Che |
|
| January 22, 2024 |
LGND / Ligand Pharmaceuticals Incorporated / BlackRock Inc. Passive Investment SC 13G/A 1 us53220k5048012224.txt us53220k5048012224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 16) LIGAND PHARMACEUTICALS INCORPORATED - (Name of Issuer) Common Stock - (Title of Class of Securities) 53220K504 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check t |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission Fi |
|
| December 1, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission |
|
| November 13, 2023 |
Ligand Reports Third Quarter 2023 Financial Results Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMA |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission F |
|
| November 8, 2023 |
Ligand Reports Third Quarter 2023 Financial Results Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p. |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission F |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission F |
|
| October 18, 2023 |
Exhibit 10.1 CREDIT AGREEMENT Dated as of October 12, 2023 among LIGAND PHARMACEUTICALS INCORPORATED, as the Borrower, THE SUBSIDIARIES OF THE BORROWER PARTY HERETO, as the Guarantors, CITIBANK, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, and THE LENDERS PARTY HERETO ************************************************ CITIBANK, N.A., as Sole Lead Arranger and Sole Bookrunner TABLE |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission |
|
| August 9, 2023 |
Exhibit 10.1 LIGAND PHARMACEUTICALS INCORPORATED DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY (Amended and Restated Effective August 4, 2023) I. DIRECTOR COMPENSATION Non-employee members of the board of directors (the “Board”) of Ligand Pharmaceuticals Incorporated (the “Company”) shall be eligible to receive cash and equity compensation effective as of April 19, 2023 (the “Restatement Effect |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMACEUTI |
|
| August 8, 2023 |
Ligand Reports Second Quarter 2023 Financial Results Conference Call Begins at 4:30 p. |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission Fil |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMACEUT |
|
| May 8, 2023 |
CHANGE IN CONTROL SEVERANCE AGREEMENT Exhibit 10.3 CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (“Agreement”) is made effective as of , by and between Ligand Pharmaceuticals Incorporated, a Delaware corporation (the “Company”), and (“Employee”). The parties agree as follows: 1. Definitions. For purposes of this Agreement, the following terms shall have the following meanings: (a) “Cause” shall mean |
|
| May 8, 2023 |
Exhibit 10.2 LIGAND PHARMACEUTICALS INCORPORATED DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY (Amended and Restated Effective April 19, 2023) I. DIRECTOR COMPENSATION Non-employee members of the board of directors (the “Board”) of Ligand Pharmaceuticals Incorporated (the “Company”) shall be eligible to receive cash and equity compensation effective as of April 19, 2023 (the “Restatement Effect |
|
| May 4, 2023 |
Ligand Reports First Quarter 2023 Financial Results 2023 Financial Guidance Raised Conference Call Begins at 4:30 p. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File N |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION April 26, 2023 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Ligand Pharmaceuticals Incorporated File No. |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from to . Commission File No. 001-33093 LIGAND PHARMACEUTICALS INCO |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| March 30, 2023 |
VKTX / Viking Therapeutics Inc / LIGAND PHARMACEUTICALS INC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Viking Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 92686J106 (CUSIP Number) Ligand Pharmaceuticals Incorporated 3911 Sorrento Valley Boulevard, Suite 110 San Diego, CA 92121 (858) |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission Fil |
|
| February 28, 2023 |
Exhibit 10.8 LIGAND PHARMACEUTICALS INCORPORATED AMENDED AND RESTATED SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION Effective Date: November 1, 2022 1. Purpose. The purpose of this Ligand Pharmaceuticals Incorporated Amended and Restated Severance Plan (this “Plan”) is to provide certain Severance Payments and Benefits (as defined below) to designated employees of the Company in the event of a termi |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-33093 LIGAND PHARMACEUTICALS INCO |
|
| February 28, 2023 |
Exhibit 10.14 SEPARATION AGREEMENT This Separation Agreement (this “Agreement”) is made by and between Ligand Pharmaceuticals Incorporated (the “Company”), and John Higgins (“Executive”), effective as of the Effective Date (as defined below). The Company and Executive are sometimes collectively referred to herein as the “Parties” and individually referred to as a “Party.” RECITALS WHEREAS, Executi |
|
| February 28, 2023 |
Exhibit 10.9 LIGAND PHARMACEUTICALS INCORPORATED DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY (Amended and Restated Effective April 13, 2020) I. DIRECTOR COMPENSATION Non-employee members of the board of directors (the “Board”) of Ligand Pharmaceuticals Incorporated (the “Company”) shall be eligible to receive cash and equity compensation effective as of April 13, 2020 (the “Restatement Effect |
|
| February 28, 2023 |
Exhibit 21.1 LIGAND PHARMACEUTICALS INCORPORATED LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Allergan Ligand Retinoid Therapeutics, Inc. Delaware Aramed Inc. Delaware Cita NeuroPharmaceuticals Inc. Canada CyDex Pharmaceuticals, Inc. Delaware Glycomed Incorporated California Ligand Biopharmaceuticals Incorporated Delaware Ligand Holdings UK Limited England and Wales Ligand JVR, Inc. Del |
|
| February 28, 2023 |
Exhibit 10.15 SEVERANCE AGREEMENT This Severance Agreement (“Agreement”) is made effective as of December 5, 2022, by and between Ligand Pharmaceuticals Incorporated, a Delaware corporation (the “Company”), and Todd C. Davis (“Employee”). The parties agree as follows: 1. Definitions. For purposes of this Agreement, the following terms shall have the following meanings: (a) “Cause” shall mean any o |
|
| February 22, 2023 |
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results 2023 Financial Guidance Raised Conference Call Begins at 4:30 p. |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission |
|
| February 10, 2023 |
LGND / Ligand Pharmaceuticals Inc. / JANUS HENDERSON GROUP PLC - JHG PLC OWNS >5% Passive Investment SC 13G/A 1 ligand02102023.txt JHG PLC OWNS >5% UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 3* Name of Issuer: LIGAND PHARMACEUTICALS INCORPORATED Title of Class of Securities: Common Stock CUSIP Number: 53220K504 Date of Event Which Requires Filing of this Statement: 12/31/2022 Check the appropriate b |
|
| February 9, 2023 |
SC 13G/A 1 tm235848d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 9)* Ligand Pharmaceuticals Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 5 |
|
| February 9, 2023 |
VKTX / Viking Therapeutics Inc / LIGAND PHARMACEUTICALS INC - SC 13D/A Activist Investment SC 13D/A 1 d461604dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Viking Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 92686J106 (CUSIP Number) Ligand Pharmaceuticals Incorporated 3911 Sorrento Valley Boulevard, Suite |
|
| February 9, 2023 |
LGND / Ligand Pharmaceuticals Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01309-ligandpharmaceutical.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Ligand Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 53220K504 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate bo |
|
| February 9, 2023 |
EX-99.1 2 d461604dex991.htm EX-99.1 Exhibit 99.1 INFORMATION REGARDING THE DIRECTOR AND EXECUTIVE OFFICERS OF LIGAND PHARMACEUTICALS INCORPORATED AND METABASIS THERAPEUTICS, INC. The names and the principal occupations of the current directors and executive officers of Ligand Pharmaceuticals Incorporated (“Ligand”) are set forth below. The business address of each of the individuals named below is |
|
| February 6, 2023 |
LGND / Ligand Pharmaceuticals Inc. / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING LIGAND PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 53220K504 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE I |
|
| January 26, 2023 |
LGND / Ligand Pharmaceuticals Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us53220k5048012623.txt us53220k5048012623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 15) LIGAND PHARMACEUTICALS INCORPORATED - (Name of Issuer) Common Stock - (Title of Class of Securities) 53220K504 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check t |
|
| January 20, 2023 |
LGND / Ligand Pharmaceuticals Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us53220k5048012023.txt us53220k5048012023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 14) LIGAND PHARMACEUTICALS INCORPORATED - (Name of Issuer) Common Stock - (Title of Class of Securities) 53220K504 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check t |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission F |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMA |
|
| November 8, 2022 |
AMENDED AND RESTATED EMPLOYEE MATTERS AGREEMENT Exhibit 10.1 AMENDED AND RESTATED EMPLOYEE MATTERS AGREEMENT This AMENDED AND RESTATED EMPLOYEE MATTERS AGREEMENT (this ?Agreement?), dated as of August 18, 2022, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (the ?Company?), OmniAb, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (?SpinCo?), Avista Public Acquisition Corp. II, a |
|
| November 7, 2022 |
Exhibit 99.1 Contacts: Ligand Pharmaceuticals Incorporated LHA Investor Relations Simon Latimer Bruce Voss Email: [email protected] Email: [email protected] Phone: (858) 550-7766 Phone: (310) 691-7100 Twitter: @LigandLGND Ligand Reports Third Quarter 2022 Financial Results Increased 2022 Financial Guidance Analyst and Investor Day to be Held on Tuesday December 13 in New York City Conference Call |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission F |
|
| November 4, 2022 |
Exhibit 10.1 TAX MATTERS AGREEMENT by and among OMNIAB, INC. (F/K/A AVISTA PUBLIC ACQUISITION CORP. II) LIGAND PHARMACEUTICALS INCORPORATED and OMNIAB OPERATIONS, INC. (F/K/A OMNIAB, INC.) Dated as of November 1, 2022 TABLE OF CONTENT i ii TAX MATTERS AGREEMENT This TAX MATTERS AGREEMENT (this ?Agreement?), is entered into as of November 1, 2022 by and among OmniAb, Inc., a Delaware corporation (f |
|
| November 4, 2022 |
Unaudited Pro Forma Condensed Consolidated Financial Statements Exhibit 99.1 Unaudited Pro Forma Condensed Consolidated Financial Statements On November, 1, 2022 (the ?Distribution Date?), Ligand Pharmaceuticals Incorporated (?Ligand,? ?Company,? ?we,? ?us,? or ?our?) completed the separation (the ?Separation?) of its antibody discovery business and certain related assets and liabilites (the ?OmniAb Business?) through a spin-off of OmniAb Operations, Inc. (for |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission F |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Delaware 001-33093 77-0160744 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| October 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Delaware 001-33093 77-0160744 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| October 3, 2022 |
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off Exhibit 99.1 Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off EMERYVILLE, Calif. (October 3, 2022) ? Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of shares of common stock of OmniAb, Inc. to be distributed to Ligand shareholders in order to effec |
|
| September 30, 2022 |
Exhibit 1.2 LIGAND PHARMACEUTICALS INCORPORATED Common Stock ($0.001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT September 30, 2022 STIFEL, NICOLAUS & COMPANY, INCORPORATED 787 7th Avenue, 11th Floor New York, NY 10019 Ladies and Gentlemen: Ligand Pharmaceuticals Incorporated, a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein |
|
| September 30, 2022 |
As filed with the Securities and Exchange Commission on September 30, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 30, 2022 Registration No. |
|
| September 30, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ligand Pharmaceuticals Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate(5) Amount of Registration Fee(5) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Fees to Be Paid Equity Common Stock, $0. |
|
| September 30, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Delaware 001-33093 77-0160744 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| September 30, 2022 |
Exhibit 4.3 LIGAND PHARMACEUTICALS INCORPORATED INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Sect |
|
| August 24, 2022 |
Filed by: Ligand Pharmaceuticals Incorporated Commission File No.: 001-33093 Pursuant to Rule 425 under the Securities Act of 1933 Subject Company: Avista Public Acquisition Corp. II (Commission File No.: 001-40720) Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI? (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Firs |
|
| August 10, 2022 |
As filed with the Securities and Exchange Commission on August 10, 2022 As filed with the Securities and Exchange Commission on August 10, 2022 Registration No. |
|
| August 10, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Ligand Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| August 9, 2022 |
LIGAND PHARMACEUTICALS INCORPORATED 2022 EMPLOYMENT INDUCEMENT PLAN NOTICE OF GRANT OF STOCK OPTION Exhibit 10.3 LIGAND PHARMACEUTICALS INCORPORATED 2022 EMPLOYMENT INDUCEMENT PLAN NOTICE OF GRANT OF STOCK OPTION Ligand Pharmaceuticals Incorporated, a Delaware corporation (the ?Corporation?), pursuant to its 2022 Employment Inducement Plan (the ?Plan?), hereby grants to the holder listed below (?Optionee?) a stock option to purchase the number of shares (?Shares?) of Common Stock of the Corporat |
|
| August 9, 2022 |
Exhibit 10.5 Performance-Based RSU Form LIGAND PHARMACEUTICALS INCORPORATED 2022 EMPLOYMENT INDUCEMENT PLAN RESTRICTED STOCK UNIT GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT Ligand Pharmaceuticals Incorporated, a Delaware corporation (the ?Corporation?), pursuant to its 2022 Employment Inducement Plan (the ?Plan?), hereby grants to the holder listed below (?Participant?), an award of restrict |
|
| August 9, 2022 |
2022 Employment Inducement Plan Exhibit 10.2 LIGAND PHARMACEUTICALS INCORPORATED 2022 EMPLOYMENT INDUCEMENT PLAN Article 1 GENERAL PROVISIONS I.PURPOSE OF THE PLAN This 2022 Employment Inducement Plan is intended to promote the interests of Ligand Pharmaceuticals Incorporated, a Delaware corporation, by providing Eligible Individuals in the Corporation?s and its Subsidiaries? service with the opportunity to acquire a proprietary |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMACEUTI |
|
| August 9, 2022 |
Exhibit 10.4 LIGAND PHARMACEUTICALS INCORPORATED 2022 EMPLOYMENT INDUCEMENT PLAN RESTRICTED STOCK UNIT GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT Ligand Pharmaceuticals Incorporated, a Delaware corporation (the ?Corporation?), pursuant to its 2022 Employment Inducement Plan (the ?Plan?), hereby grants to the holder listed below (?Participant?), an award of restricted stock units (?Restricted |
|
| August 8, 2022 |
Exhibit 99.1 Contacts: Ligand Pharmaceuticals Incorporated LHA Investor Relations Simon Latimer Bruce Voss Email: [email protected] Email: [email protected] Phone: (858) 550-7766 Phone: (310) 691-7100 Twitter: @LigandLGND Ligand Reports Second Quarter 2022 Financial Results Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (August 8, 2022) ? L |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission Fil |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| June 29, 2022 |
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors Exhibit 99.1 Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors EMERYVILLE (June 29, 2022) ? Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (?Ligand? or ?the Company?) announces the appointment of Jason Haas to the Company's Board of Directors. Mr. Haas brings more than 30 years of healthcare investment banking and corporate finance experience to Ligand. ?Jason is a particula |
|
| June 21, 2022 |
Analyst Teach - In June 21, 2022 11 am EDT Exhibit 99.1 Analyst Teach - In June 21, 2022 11 am EDT 2 LEGAL DISCLAIMERS About this Presentation This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) between Avista Public Acquisition Corp. II (APAC) and OmniAb, Inc. (OmniAb), a wholly owned subsidiary of Ligand |
|
| June 21, 2022 |
Analyst Teach - In June 21, 2022 11 am EDT Exhibit 99.1 Analyst Teach - In June 21, 2022 11 am EDT 2 LEGAL DISCLAIMERS About this Presentation This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) between Avista Public Acquisition Corp. II (APAC) and OmniAb, Inc. (OmniAb), a wholly owned subsidiary of Ligand |
|
| June 21, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Delaware 001-33093 77-0160744 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Delaware 001-33093 77-0160744 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| June 13, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Ligand Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| June 13, 2022 |
As filed with the Securities and Exchange Commission on June 13, 2022 As filed with the Securities and Exchange Commission on June 13, 2022 Registration No. |
|
| June 13, 2022 |
LIGAND PHARMACEUTICALS INCORPORATED NOTICE OF GRANT OF NON-QUALIFIED INDUCEMENT STOCK OPTION Exhibit 10.2 LIGAND PHARMACEUTICALS INCORPORATED NOTICE OF GRANT OF NON-QUALIFIED INDUCEMENT STOCK OPTION As inducement material to the decision by the individual listed below (?Optionee?) to accept employment with OmniAb, Inc. (?OmniAb?), a subsidiary of Ligand Pharmaceuticals Incorporated (the ?Corporation?), the Corporation hereby grants to Optionee a non-qualified stock option to purchase the |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMACEUT |
|
| May 5, 2022 |
Filed by: Ligand Pharmaceuticals Incorporated Commission File No.: 001-33093 Pursuant to Rule 425 under the Securities Act of 1933 Subject Company: Avista Public Acquisition Corp. II (Commission File No.: 001-40720) Contacts: Ligand Pharmaceuticals Incorporated LHA Investor Relations Simon Latimer Bruce Voss Email: [email protected] Email: [email protected] Phone: (858) 550-7766 Phone: (310) 691-7 |
|
| May 4, 2022 |
Exhibit 99.1 Contacts: Ligand Pharmaceuticals Incorporated LHA Investor Relations Simon Latimer Bruce Voss Email: [email protected] Email: [email protected] Phone: (858) 550-7766 Phone: (310) 691-7100 Twitter: @LigandLGND Ligand Reports First Quarter 2022 Financial Results Conference Call Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (May 4, 2022) ? Ligand Pharmaceuticals Incorporated |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File N |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| March 24, 2022 |
Exhibit 10.1 Execution Version EMPLOYEE MATTERS AGREEMENT This EMPLOYEE MATTERS AGREEMENT (this ?Agreement?), dated as of March 23, 2022, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (the ?Company?), OmniAb, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (?SpinCo?), Avista Public Acquisition Corp. II, a Cayman Islands exempted |
|
| March 24, 2022 |
Exhibit 2.4 Execution Version AMENDED AND RESTATED FORWARD PURCHASE AGREEMENT This Amended and Restated Forward Purchase Agreement (this ?Agreement?) is entered into as of March 23, 2022, by and among Avista Public Acquisition Corp. II, a Cayman Islands exempted company (the ?Company?), Avista Acquisition LP II, a Cayman Islands exempted limited partnership (the ?Purchaser?), and OmniAb, Inc., a D |
|
| March 24, 2022 |
Exhibit 2.3 Execution Version March 23, 2022 Avista Public Acquisition Corp. II 65 East 55th Street, 18th Floor New York, NY 10022 Re: Letter Agreement Ladies and Gentlemen: Reference is made to that certain Agreement and Plan of Merger, dated as of March 23, 2022 (the ?Merger Agreement?), by and among Ligand Pharmaceuticals Incorporated (?Ligand?), a Delaware corporation, OmniAb, Inc., a Delaware |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Delaware 001-33093 77-0160744 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| March 24, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Delaware 001-33093 77-0160744 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| March 24, 2022 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER DATED AS OF MARCH 23, 2022 by and among LIGAND PHARMACEUTICALS INCORPORATED, OMNIAB, INC., AVISTA PUBLIC ACQUISITION CORP. II and ORWELL MERGER SUB INC. -i- TABLE OF CONTENTS Page Article I DEFINITIONS 4 Section 1.1 Definitions 4 Section 1.2 Cross References 23 Section 1.3 Interpretation 24 Article II THE MERGER 26 Section 2.1 The Merger 2 |
|
| March 24, 2022 |
Exhibit 2.2 Execution Version SEPARATION AND DISTRIBUTION AGREEMENT by and among LIGAND PHARMACEUTICALS INCORPORATED, OMNIAB, INC. and AVISTA PUBLIC ACQUISITION CORP. II Dated as of March 23, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INTERPRETATION 2 Section 1.1 General 2 Section 1.2 References; Interpretation 21 ARTICLE II THE SEPARATION 21 Section 2.1 General 21 Section 2.2 Restructu |
|
| March 23, 2022 |
Exhibit 99.3 Project Orwell Transcript Transcribed By: FINSIGHT 530 7th Avenue New York, NY 10018 DISCLAIMER: FINSIGHT makes every effort to ensure an accurate transcription. Enclosed is the output of transcribing from an audio recording. Although the transcription is largely accurate, in some cases, it may be incomplete or inaccurate due to inaudible passages or transcription errors. This transcr |
|
| March 23, 2022 |
Exhibit 99.3 Project Orwell Transcript Transcribed By: FINSIGHT 530 7th Avenue New York, NY 10018 DISCLAIMER: FINSIGHT makes every effort to ensure an accurate transcription. Enclosed is the output of transcribing from an audio recording. Although the transcription is largely accurate, in some cases, it may be incomplete or inaccurate due to inaudible passages or transcription errors. This transcr |
|
| March 23, 2022 |
Exhibit 99.2 ANCHORED SPIN-OFF INVESTOR PRESENTATION March 2022 2 LEGAL DISCLAIMERS About this Presentation This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) between Avista Public Acquisition Corp. II (APAC) and OmniAb, Inc. (OmniAb), a wholly owned subsidiary o |
|
| March 23, 2022 |
Exhibit 99.1 Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II Transaction will result in OmniAb becoming an independent publicly traded company Ligand?s shareholders to receive 100% of Ligand?s shares in OmniAb through a tax-free distribution immediately prior to the merger EMERYVILLE, CALIFORNIA and NEW YORK (March 23, 2022) ? Ligand Pharmaceuticals In |
|
| March 23, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Delaware 001-33093 77-0160744 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in its Charter) Delaware 001-33093 77-0160744 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| March 23, 2022 |
Exhibit 99.2 ANCHORED SPIN-OFF INVESTOR PRESENTATION March 2022 2 LEGAL DISCLAIMERS About this Presentation This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) between Avista Public Acquisition Corp. II (APAC) and OmniAb, Inc. (OmniAb), a wholly owned subsidiary o |
|
| March 23, 2022 |
Exhibit 99.1 Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II Transaction will result in OmniAb becoming an independent publicly traded company Ligand?s shareholders to receive 100% of Ligand?s shares in OmniAb through a tax-free distribution immediately prior to the merger EMERYVILLE, CALIFORNIA and NEW YORK (March 23, 2022) ? Ligand Pharmaceuticals In |
|
| February 28, 2022 |
Exhibit 21.1 LIGAND PHARMACEUTICALS INCORPORATED LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Ab Initio Biotherapeutics, Inc. Delaware Allergan Ligand Retinoid Therapeutics, Inc. Delaware Cita NeuroPharmaceuticals Inc. Canada Crystal Bioscience, Inc. California CyDex Pharmaceuticals, Inc. Delaware Glycomed Incorporated California Icagen, LLC Delaware Ligand Biopharmaceuticals Incorporat |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-33093 LIGAND PHARMACEUTICALS INCO |
|
| February 28, 2022 |
Exhibit 10.39 OFFICE/LABORATORY LEASE BETWEEN EMERY STATION OFFICE II, LLC (LANDLORD) AND LIGAND PHARMACEUTICALS INCORPORATED (TENANT) 5980 Horton Street Emeryville, California 00056263.8 TABLE OF CONTENTS Page Article 1 BASIC LEASE PROVISIONS 1 1.1 BASIC LEASE PROVISIONS 1 1.2 ENUMERATION OF EXHIBITS AND RIDER(S) 5 1.3 DEFINITIONS 5 Article 2 PREMISES, TERM, FAILURE TO GIVE POSSESSION, AND PARKIN |
|
| February 28, 2022 |
Exhibit 10.37 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUBLICENSE AGREEMENT THIS SUBLICENSE AGREEMENT (the ?Agreement?) is made and entered into effective as of February 16, 2012 (the ?Effective Date?) by and between Ligand Pharmaceuticals Inc |
|
| February 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission |
|
| February 17, 2022 |
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results Conference Call Begins at 4:30 p. |
|
| February 14, 2022 |
LGND / Ligand Pharmaceuticals Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ligand Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 53220K504 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2022 |
LGND / Ligand Pharmaceuticals Inc. / CARDINAL CAPITAL MANAGEMENT LLC /CT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2022 |
LGND / Ligand Pharmaceuticals Inc. / WASATCH ADVISORS INC Passive Investment SCHEDULE 13G Amendment No. 1 Name of Issuer: Ligand Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 53220K504 Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 195,197 Item 6: Shared Votin |
|
| February 11, 2022 |
LGND / Ligand Pharmaceuticals Inc. / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING LIGAND PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 53220K504 (CUSIP NUMBER) 12/31/2021 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDUL |
|
| February 10, 2022 |
LGND / Ligand Pharmaceuticals Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Ligand Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 53220K504 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 8)* Ligand Pharmaceuticals Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 53220K504 (CUSIP Number) December 31, 2021 |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2* Name of Issuer: LIGAND PHARMACEUTICALS INCORPORATED Title of Class of Securities: Common Stock CUSIP Number: 53220K504 Date of Event Which Requires Filing of this Statement: 12/31/2021 Check the appropriate box to designate the rule pursuant to which this |
|
| January 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission F |
|
| January 27, 2022 |
LGND / Ligand Pharmaceuticals Inc. / BlackRock Inc. Passive Investment us53220k5048012722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 13) LIGAND PHARMACEUTICALS INCORPORATED - (Name of Issuer) Common Stock - (Title of Class of Securities) 53220K504 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 25, 2022 |
LGND / Ligand Pharmaceuticals Inc. / BlackRock Inc. Passive Investment us53220k5048012522.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 12) LIGAND PHARMACEUTICALS INCORPORATED - (Name of Issuer) Common Stock - (Title of Class of Securities) 53220K504 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 14, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2022 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission F |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-33093 LIGAND PHARMA |
|
| November 9, 2021 |
Exhibit 99.1 Contacts: Ligand Pharmaceuticals Incorporated LHA Investor Relations Simon Latimer Bruce Voss Email: [email protected] Email: [email protected] Phone: (858) 550-7766 Phone: (310) 691-7100 Twitter: @LigandLGND Ligand Reports Third Quarter 2021 Financial Results Conference Call Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (November 9, 2021) ? Ligand Pharmaceuticals Incorpor |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission F |
|
| October 12, 2021 |
LGND / Ligand Pharmaceuticals Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Ligand Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 53220K504 Date of Event Which Requires Filing of this Statement: September 30, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission Fi |
